Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Gliosarcoma × ficlatuzumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 120 Radiotherapy 80 Bevacizumab 41 Radiation 29 Carmustine 26 Irinotecan 21 Erlotinib Hydrochloride 21 Magnetic Resonance Spectroscopy 18 Chemotherapy, Adjuvant 17 Surgical Procedures, Operative 13 O(6)-benzylguanine 13 Carboplatin 13 sargramostim 12 Radiotherapy, Intensity-Modulated 11 Radiotherapy, Conformal 11 Imatinib Mesylate 9 Thalidomide 8 motexafin gadolinium 7 Radiosurgery 7 Procarbazine 7 Gene Expression Profiling 7 Gefitinib 7 Filgrastim 7 Drug Therapy 7 Cyclophosphamide 7 pembrolizumab 6 cediranib 6 Vorinostat 6 Sirolimus 6 Lomustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡